Search Results | Blood | American Society of Hematology

1-20 of 1253

2 3 4 5

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

DOI: https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

DOI: https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

DOI: https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Journal Articles

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Blood (2020) 135 (24): 2182–2191.

DOI: https://doi.org/10.1182/blood.2019004710

Published: 2020

Includes: Supplemental data

Journal Articles

Impact of Cytoreductive Therapy and Depth of Response before Allogeneic Transplantation for Advanced Myelodysplastic Syndrome

Yu Wang, Lan-Ping Xu, Kaiyan Liu, MD PhD, Xiao-Hui Zhang, Chen-hua Yan, Xiao-Jun Huang, MD

Blood (2019) 134 (Supplement_1): 4607.

DOI: https://doi.org/10.1182/blood-2019-124046

Published: 2019

Journal Articles

Dissecting the Immune Cell Progeny of CAR-Expressing Hematopoietic Stem Cells in a Humanized Mouse Model

Heng-Yi Liu, Nezia Rahman, Tzu-Ting Chiou, PhD, Satiro N. De Oliveira, MD

Blood (2019) 134 (Supplement_1): 4640.

DOI: https://doi.org/10.1182/blood-2019-129746

Published: 2019

Journal Articles

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Christina Rautenberg, MD, Stefanie Stepanow, Michael Lauseker, Ulrich Germing, MD, Paul Jäger, Stefanie Geyh, Esther Schuler, Karl Köhrer, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2019) 134 (Supplement_1): 4612.

DOI: https://doi.org/10.1182/blood-2019-126565

Published: 2019

Journal Articles

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Blood (2019) 134 (Supplement_1): 4614.

DOI: https://doi.org/10.1182/blood-2019-128004

Published: 2019

Journal Articles

Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Christopher D'Angelo, MD, Sailendharan Sudakaran, PhD, Peiman Hematti, MD, Fotis Asimakopoulos, PhDMBBChir,, Craig Augustine, MBA, Nasia Safdar, MD PhD, Natalie Scott Callander, MD

Blood (2019) 134 (Supplement_1): 4653.

DOI: https://doi.org/10.1182/blood-2019-123530

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

DOI: https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia

Malin S Nilsson, MSc, Alexander Hallner, PhD, Mats Brune, MD PhD, Staffan Nilsson, PhD, Fredrik B Thorén, PhD, Anna Martner, PhD, Kristoffer Hellstrand, MD PhD

Blood (2019) 134 (Supplement_1): 1318.

DOI: https://doi.org/10.1182/blood-2019-130345

Published: 2019

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

DOI: https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 1541.

DOI: https://doi.org/10.1182/blood-2019-127494

Published: 2019

Journal Articles

Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype

Sharad Khurana, MDMSc, Michael G. Heckman, Jordan Cochuyt, Fiona E. Craig, MBBS, Zaid Abdel Rahman, MD, Patricia Greipp, DO, Lisa Z. Sproat, MD, Mark Litzow, MD, James M. Foran, MD, Liuyan Jiang

Blood (2019) 134 (Supplement_1): 5210.

DOI: https://doi.org/10.1182/blood-2019-123286

Published: 2019

Journal Articles

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Joanne L C Tan, MBBS, Eric Wong, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Radha Ramanan, MBBS, Andrew B M Lim, David Ritchie, MD PhD

Blood (2019) 134 (Supplement_1): 5662.

DOI: https://doi.org/10.1182/blood-2019-122363

Published: 2019

Journal Articles

Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis

Nishi Shah, MBBS, MPH, Mohammad Kazemi, Stephen Zachary Peeke, MD, Lizamarie Bachier-rodriguez, R.Alejandro Sica, MD, Noah Kornblum, MD, Ira Braunschweig, MD, Aditi Shastri, MD, Amit Verma, MBBS, Ioannis Mantzaris, MD MS

Blood (2019) 134 (Supplement_1): 426.

DOI: https://doi.org/10.1182/blood-2019-123168

Published: 2019

Journal Articles

Easix for Prediction of Survival in Myelodysplastic Syndromes

Almuth Maria Anni Merz, MD, Ulrich Germing, MD, Guido Kobbe, MD, Jennifer Kaivers, MD, Anna Jauch, Aleksandar Radujkovic, MD, Manuela Hummel, Axel Benner, Maximilian Merz, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 1722.

DOI: https://doi.org/10.1182/blood-2019-122622

Published: 2019

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

DOI: https://doi.org/10.1182/blood-2019-125967

Published: 2019

Journal Articles

Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Blood (2019) 134 (Supplement_1): 3596.

DOI: https://doi.org/10.1182/blood-2019-126028

Published: 2019

Journal Articles

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Adam J. Mead, MD PhD, Tim Somervaille, Professor, MD, Nauman M Butt, MD, Waseem Nagi, MD FRCPath, Alastair J Whiteway, MBBS, Suriya Kirkpatrick, MD, Ciro R Rinaldi, MD PhD, Catherine Roughley, MD, Sam Ackroyd, MD, Joanne Ewing, PhDBMBS BSc FRPATH, Pratap Neelakantan, MD FRCPath, Mamta Garg, MD FRCP, FRCPath, Claire N Harrison, Professor, David Tucker, MD, Rozinder Bains, Gavin Chiu, MBBS, MRCGP, MFPM, DPM, BSc, Joe Hickey, PhD

Blood (2019) 134 (Supplement_1): 1671.

DOI: https://doi.org/10.1182/blood-2019-124686

Published: 2019

2 3 4 5

NARROW

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Impact of Cytoreductive Therapy and Depth of Response before Allogeneic Transplantation for Advanced Myelodysplastic Syndrome

Dissecting the Immune Cell Progeny of CAR-Expressing Hematopoietic Stem Cells in a Humanized Mouse Model

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Hispanic and Black Patients with Adult B-Cell Acute Lymphoblastic Leukemia Have a Significantly Worse Survival in the Modern Era - a SEER 2010-2016 Analysis

Easix for Prediction of Survival in Myelodysplastic Syndromes

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only